Skip to main
DNTH
DNTH logo

DNTH Stock Forecast & Price Target

DNTH Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dianthus Therapeutics, Inc. is advancing its clinical-stage pipeline with a focused approach on developing next-generation complement therapeutics, particularly DNTH103, which is a subcutaneous active C1s antibody aimed at treating severe autoimmune and inflammatory diseases. Recent updates indicate a positive adjustment in the company's financial outlook, showcasing a target increase from $44 to $46 due to improved net cash positions and a lower anticipated share count. The favorable early data from clinical trials, specifically relating to the differentiation of claseprubart in its treatments, boosts confidence in the company’s potential for growth and innovation in the biotechnology sector.

Bears say

Dianthus Therapeutics Inc. faces significant challenges regarding its financial stability, as the company's ability to advance its pipeline depends heavily on securing adequate funding. If funds are not raised to support ongoing research and development efforts, the progress of their drug candidates, including DNTH103, may be adversely affected. Additionally, the decision to remove an assumed offering for FY28 and the subsequent lowering of FY25 share count further indicates concerns about future financing and shareholder dilution.

DNTH has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Magenta Therapeutics Inc (DNTH) Forecast

Analysts have given DNTH a Strong Buy based on their latest research and market trends.

According to 8 analysts, DNTH has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Magenta Therapeutics Inc (DNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.